We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+15.34%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$338M
AUM Growth
+$65.4M
Cap. Flow
+$44.6M
Cap. Flow %
13.18%
Top 10 Hldgs %
27.92%
Holding
106
New
39
Increased
24
Reduced
12
Closed
28

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$8.7M
2
GSK icon
GSK
GSK
+$7.94M
3
CNC icon
Centene
CNC
+$7.26M
4
EXAS
Exact Sciences
EXAS
+$6.94M
5
SHPG
Shire pic
SHPG
+$6.83M

Top Sells

Rank Stock Value
1
ATHN
Athenahealth, Inc.
ATHN
+$9.99M
2
IEV icon
iShares Europe ETF
IEV
+$7.22M
3
NUVA
NuVasive, Inc.
NUVA
+$7.07M
4
HUM icon
Humana
HUM
+$6.83M
5
AET
Aetna Inc
AET
+$4.84M

Sector Composition

Rank Sector Weight
1 Healthcare 73.98%
2 Financials 0%
3 Industrials 0%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
51
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.23M 0.66%
+60,598
New +$1.53M
COLL icon
52
Collegium Pharmaceutical
COLL
$882M
$2.01M 0.6%
+200,000
New +$2.97M
ARRY
53
DELISTED
Array Biopharma Inc
ARRY
$1.99M 0.59%
223,000
+65,640
+42% +$698K
CLVS
54
DELISTED
Clovis Oncology, Inc.
CLVS
$1.99M 0.59%
+31,250
New +$1.9M
PCRX icon
55
Pacira BioSciences
PCRX
$974M
$1.94M 0.57%
+42,500
New +$1.84M
OTIC
56
DELISTED
Otonomy, Inc.
OTIC
$1.68M 0.5%
+137,500
New +$2M
AIMT
57
DELISTED
Aimmune Therapeutics
AIMT
$1.52M 0.45%
+70,000
New +$1.44M
JAZZ icon
58
Jazz Pharmaceuticals
JAZZ
$16.7B
$1.48M 0.44%
+10,200
New +$1.33M
ANIP icon
59
ANI Pharmaceuticals
ANIP
$1.72B
$1.43M 0.42%
28,875
+2,625
+10% +$147K
ARDX icon
60
Ardelyx
ARDX
$997M
$1.3M 0.38%
+102,500
New +$1.35M
VIVE
61
DELISTED
VIVEVE MED INC
VIVE
$1.23M 0.36%
194
+37
+24% +$180K
DMK
62
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$956K 0.28%
+3,214
New +$811K
FLXN
63
DELISTED
Flexion Therapeutics, Inc.
FLXN
$942K 0.28%
+35,000
New +$715K
SGYP
64
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$932K 0.28%
+200,000
New +$1.16M
WMGIZ
65
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$899K 0.27%
587,241
+305
+0.1% +$462
ADYX
66
DELISTED
Adynxx Inc
ADYX
$610K 0.18%
20,134
+10,417
+107% +$369K
ZYNE
67
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$603K 0.18%
+30,000
New +$596K
ELGX
68
CALL
DELISTED
Endologix Inc
ELGX
$547K 0.16%
+7,550
New +$499K
AGRX
69
DELISTED
Agile Therapeutics
AGRX
$527K 0.16%
82
– –
NVCN
70
DELISTED
Neovasc Inc.
NVCN
$520K 0.15%
+14
New +$531K
AXGN icon
71
Axogen
AXGN
$2.59B
$519K 0.15%
49,700
+25,000
+101% +$255K
STML
72
DELISTED
Stemline Therapeutics, Inc.
STML
$513K 0.15%
+60,000
New +$547K
STDY
73
DELISTED
SteadyMed Ltd
STDY
$461K 0.14%
79,434
– –
FPRX
74
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$325K 0.1%
8,982
-5,168
-37% -$228K
ARAY icon
75
CALL
Accuray
ARAY
$34.9M
$238K 0.07%
+50,000
New +$260K
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q1 2017 Portfolio in Review

As of Q1 2017, Pura Vida Investments held 106 positions worth $338M, up 24% from $273M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Pura Vida Investments deployed $44.6M of net new capital in Q1 2017, opening 39 new positions and adding to 24 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 67,500 shares worth $8.18M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 53% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was AbbVie, an estimated $4.26M trimmed.

  • Pura Vida Investments's largest Q1 2017 buy was Alexion Pharmaceuticals: 67,500 shares worth $8.18M.
  • Pura Vida Investments added most to Allergan plc in Q1 2017, an estimated $5.16M increase.
  • Pura Vida Investments's biggest Q1 2017 reduction was AbbVie, cutting an estimated $4.26M.
  • Pura Vida Investments fully exited Athenahealth, Inc. in Q1 2017, selling an estimated $9.99M.
  • Pura Vida Investments's ten largest holdings make up 28% of its $338M portfolio in Q1 2017.
  • Pura Vida Investments opened 39 new positions and closed 28 in Q1 2017.
  • Pura Vida Investments's portfolio value rose 24% quarter-over-quarter to $338M.

Based on Pura Vida Investments's 13F filing for Q1 2017, filed 15 May 2017.